The treatment was well tolerated by most patients, and only some of them experienced minor adverse effects at the beginning of the trial. Conclusion: Calcitriol dosage used (0.25mcg/24h) is safe for FRDA patients and it increases frataxin levels. We cannot rule out that higher doses administered longer could yield neurological benefits.